Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Capital Raises) (Narrative) (Details)

v3.23.1
Stockholders' Equity (Capital Raises) (Narrative) (Details) - USD ($)
 1 Months Ended 3 Months Ended
Jan. 27, 2023
Dec. 27, 2022
Dec. 16, 2022
Oct. 11, 2022
Mar. 04, 2022
Apr. 23, 2021
Oct. 23, 2020
Feb. 28, 2023
Mar. 31, 2021
Nov. 30, 2020
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Common Stock, par value                     $ 0.001   $ 0.001
Proceeds from Issuance of Common Stock                     $ 447,000 $ 4,226,000  
Gain (loss) on common stock warrant liabilities                     (6,678,000)    
Proceeds from debt                     0 $ 42,129,000  
Journey | 8% Cumulative Convertible Preferred Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, price per share                       $ 25.00  
Stock offering, gross proceeds                       $ 800,000  
Preferred Stock, dividend rate percentage                 8.00%        
Placement agent fees                       $ 100,000  
Checkpoint | Common Stock Warrants [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Gain (loss) on common stock warrant liabilities     $ (1,200,000)               $ 7,600,000    
Net proceeds     $ 6,700,000                    
Avenue Therapeutics, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, number of shares issued 448,000                        
Shares issued       3,636,365                  
Number of warrants to purchase shares       545,454                  
Unit Price Per Share $ 1.55                        
Number of common stock (in units)       1                  
Number of warrants (in units)       1                  
Proceeds from Issuance of Common Stock       $ 10,300,000                  
Avenue Therapeutics, Inc [Member] | InvaGen [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Percentage of shares repurchased       100.00%                  
Purchase price of shares repurchased       $ 3,000,000                  
Avenue Therapeutics, Inc [Member] | Pre-Funded Warrants [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Exercise price of warrants 0.0001     $ 0.0001                  
Unit Price Per Share $ 1.5499     3.2999                  
Avenue Therapeutics, Inc [Member] | Common Stock and Pre-funded Warrants                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Unit Price Per Share       $ 3.30                  
Number of warrants (in units)       1                  
Urica | Convertible Class B Preferred Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, number of shares issued   101,334                      
Stock offering, price per share   $ 25.00                      
Stock offering, gross proceeds   $ 2,500,000           $ 900,000          
Stock offering, aggregate fees paid   $ 300,000           100,000          
Sale of stock, net proceeds               $ 800,000          
Preferred Stock, dividend rate percentage   8.00%                      
Runway Note [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Proceeds from debt         $ 30,000,000.0                
Debt instrument face amount         75,000,000.0                
Runway Note [Member] | Financial Milestones [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Debt instrument face amount         $ 45,000,000.0                
At the Market Offering [Member] | MLV & Co. and FBR Capital Markets & Co [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, number of shares issued                     600,000    
Amount available for future stock offerings                     $ 11,100,000    
At the Market Offering [Member] | Common Stock [Member] | Cantor Fitzgerald & Co., Oppenheimer & Co., Inc., H.C. Wainwright & Co. Inc., Jones Trading Institutional Services LLC. B. Riley and Dawson James Securities, Inc [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, price per share                     $ 0.76    
Stock offering, gross proceeds                     $ 500,000    
At the Market Offering [Member] | Mustang | Common Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, number of shares issued                       200,000  
Stock offering, price per share                       $ 15.00  
Stock offering, gross proceeds                       $ 2,800,000  
Shelf Registration Statement [Member] | Checkpoint                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Amount available for future stock offerings                     14,800,000    
Shelf Registration Statement [Member] | Maximum | Checkpoint                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, aggregate offering permitted by the agreement                   $ 100,000,000      
Shelf Registration Statement [Member] | Maximum | Mustang                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, aggregate offering permitted by the agreement           $ 200,000,000              
Mustang 2020 S-3 [Member] | Mustang                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Stock offering, aggregate offering permitted by the agreement             $ 100,000,000.0            
Amount available for future stock offerings                     $ 8,000,000.0